4178 — StemCyte International Income Statement
0.000.00%
Last trade - 00:00- TWD3.80bn
- TWD1.89bn
- TWD368.91m
Annual income statement for StemCyte International, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 348 | 363 | 383 | 369 |
| Cost of Revenue | ||||
| Gross Profit | 122 | 106 | 118 | 127 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 507 | 703 | 642 | 599 |
| Operating Profit | -160 | -341 | -260 | -230 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -128 | -332 | -205 | -173 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -122 | -320 | -206 | -177 |
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -54.5 | -320 | -206 | -177 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -54.5 | -320 | -206 | -177 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.642 | -1.35 | -1.13 | -0.902 |
| Dividends per Share |